Andrew Koff
Overview
Explore the profile of Andrew Koff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Nov;
42(11):1983.
PMID: 39532066
No abstract available.
2.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Oct;
42(11):1919-1935.e9.
PMID: 39393354
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. Using a large, clinically annotated cohort of patients...
3.
Fjermeros K, Ghannoum S, Geisler S, Bhargava S, Tahiri A, Klajic J, et al.
Future Oncol
. 2024 Jul;
20(32):2457-2466.
PMID: 39073142
Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be...
4.
Gleason C, Dickson M, Klein Dooley M, Antonescu C, Gularte-Merida R, Benitez M, et al.
Clin Cancer Res
. 2023 Sep;
30(4):703-718.
PMID: 37695642
Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. Patients And...
5.
DAngelo S, Richards A, Conley A, Woo H, Dickson M, Gounder M, et al.
Nat Commun
. 2022 Jun;
13(1):3477.
PMID: 35710741
PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in...
6.
Li Q, Jiang B, Guo J, Shao H, Del Priore I, Chang Q, et al.
Cancer Discov
. 2021 Sep;
12(2):356-371.
PMID: 34544752
Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over...
7.
Langthaler S, Rienmuller T, Scheruebel S, Pelzmann B, Shrestha N, Zorn-Pauly K, et al.
PLoS Comput Biol
. 2021 Jun;
17(6):e1009091.
PMID: 34157016
Lung cancer is still a leading cause of death worldwide. In recent years, knowledge has been obtained of the mechanisms modulating ion channel kinetics and thus of cell bioelectric properties,...
8.
Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A, et al.
Oncogene
. 2018 May;
37(37):5066-5078.
PMID: 29789718
CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein....
9.
Klein M, Kovatcheva M, Davis L, Tap W, Koff A
Cancer Cell
. 2018 May;
34(1):9-20.
PMID: 29731395
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many...
10.
Kovatcheva M, Klein M, Tap W, Koff A
Mol Cell Oncol
. 2018 Feb;
5(1):e1384882.
PMID: 29404388
Senescence is an irreversible form of growth arrest and is generally considered a favorable outcome of cancer therapies, yet little is known about the molecular events that distinguish this state...